In 2013, a case of HIV remission was reported in a U.S. born child (known as the “Mississippi Baby”) who was treated with three drug ART by 31 hours of life for high-risk HIV exposure from a mother with untreated HIV infection. In this infant, viral load detection reached undetectable levels by 28 days of […]
HIV Vaccine Trials Network (HVTN) Executive Director, James Kublin, MD, MPH, lead a one-day training on 3 October 2014, in Harare, aimed at orienting Zimbabwe national regulators to the work of the HVTN, the P5 Initiative in Southern Africa, and Phase I clinical trials the network is planning for implementation in the region. The P5 […]
UZCHS-CTU’s Seke South CRS has been officially selected as a protocol specific site by the US National Institutes of Health’s HIV Vaccine Trials Network (HVTN). The HVTN’s mission is to facilitate the process of testing preventative vaccines against HIV/AIDS and is a global leader in vaccine development. These will be the first ever HIV-related vaccine […]
2014 marked the 20th Anniversary of UZCHS-CTU and collaborations with UCSF in Harare, Zimbabwe. Since its inception in 1994, our studies have helped to shape national and global responses to the HIV/AIDS pandemic, and have defined policies and standards regarding the course of HIV acquisition, prevention, treatment, and care. Some examples include groundbreaking research in […]
Linking HIV prevention strategies to contraception has a significant potential for public health benefit. However, many large observational studies to date have indicated an association between the use of combined oral contraceptives or depot medroxyprogesterone acetate and HIV acquisition and transmission. To date, little research has been designed to try and explain if hormonal contraceptive […]
UZ-CTRC, in collaboration with UCSF, has been awarded continued Clinical Trials Unit (CTU) funding from the US National Institute of Allergy and Infectious Diseases (NIAID) to continue conducting high quality HIV treatment and prevention studies through 2021. The CTU will continue to operate seven clinical research sites, which operate under four NIAID sponsored research networks: […]
